Category BUSINESS

Clean Harbors Reports Financial Results for the Third Quarter of 2025

Clean Harbors Reports Financial Results for the Third Quarter of 2025

Clean Harbors Reports Strong Third-Quarter 2025 Results, Highlights Continued Growth and Margin Expansion Clean Harbors, Inc. (“Clean Harbors” or the “Company”) (NYSE: CLH), the leading provider of environmental and industrial services across North America, today announced financial results for the…

Read MoreClean Harbors Reports Financial Results for the Third Quarter of 2025

FUJIFILM Biotechnologies’ Lars Petersen Wins 2025 CPHI “CEO of the Year

FUJIFILM Biotechnologies’ CEO Lars Petersen Named “CEO of the Year” at CPHI Pharma Awards 2025 FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) specializing in biologics, vaccines, and advanced therapies, proudly announces that its President and Chief Executive…

Read MoreFUJIFILM Biotechnologies’ Lars Petersen Wins 2025 CPHI “CEO of the Year

Element Solutions to Acquire Micromax® from Celanese for $500 Million

Element Solutions to Acquire Micromax® from Celanese in $500 Million Deal, Expanding Leadership in Advanced Electronics Materials (“Element Solutions,” “ESI,” or the “Company”), a global and diversified specialty chemical technology company, announced today that it has entered into a definitive…

Read MoreElement Solutions to Acquire Micromax® from Celanese for $500 Million

Arrowhead Pharmaceuticals Finalizes Global Licensing and Collaboration Deal with Novartis

Arrowhead Pharmaceuticals Announces Completion of Global Licensing and Collaboration Agreement with Novartis Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a leading biopharmaceutical company focused on developing innovative RNA interference (RNAi) therapeutics, announced today that its previously disclosed global licensing and collaboration agreement…

Read MoreArrowhead Pharmaceuticals Finalizes Global Licensing and Collaboration Deal with Novartis

Merck Publishes Long-Term Phase 3 Data on OGSIVEO® (nirogacestat) for Desmoid Tumors in Journal of Clinical Oncology

Merck Publishes Long-Term Phase 3 DeFi Trial Results Demonstrating Sustained Efficacy and Safety of OGSIVEO® (nirogacestat) for Desmoid Tumors in Journal of Clinical Oncology Merck, a leading science and technology company, announced the publication of long-term efficacy and safety findings…

Read MoreMerck Publishes Long-Term Phase 3 Data on OGSIVEO® (nirogacestat) for Desmoid Tumors in Journal of Clinical Oncology

Materion Corporation Schedules Third Quarter 2025 Financial Results Announcement for October 29

Materion Corporation to Announce Third Quarter 2025 Financial Results on October 29, 2025 Materion Corporation (NYSE: MTRN), a leading global provider of advanced materials solutions, has announced that it will release its financial results for the third quarter of 2025…

Read MoreMaterion Corporation Schedules Third Quarter 2025 Financial Results Announcement for October 29